Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Allopurinol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH known ✓ | P47989 | 2/20 | 0.96 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.96 |
| ▸ | LMNA | P02545 | 1/20 | 0.96 |
| ▸ | TSHR | P16473 | 1/20 | 0.96 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.96 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.96 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.96 |
| ▸ | RAB9A | P51151 | 1/20 | 0.96 |
| ▸ | BLM | P54132 | 1/20 | 0.96 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | PI4KA | P42356 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.42 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.42 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.42 |
| ▸ | KDM4A | O75164 | 2/20 | 0.42 |
| ▸ | KDM4B | O94953 | 2/20 | 0.42 |
| ▸ | KDM5C | P41229 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Allopurinol SCHEMBL4628 | 0.98 | SMN1; SMN2 (1.00) | SMN1; SMN2XDHLMNATSHRADORA2A | |
| Allopurinol SCHEMBL7202471 | 0.96 | SMN1; SMN2 (0.96) | SMN1; SMN2XDHLMNATSHRADORA2A | |
| Allopurinol SCHEMBL6142914 | 0.96 | SMN1; SMN2 (0.96) | SMN1; SMN2XDHLMNATSHRADORA2A | |
| Allopurinol SCHEMBL29793328 | 0.96 | SMN1; SMN2 (0.96) | SMN1; SMN2XDHLMNATSHRADORA2A | |
| Allopurinol SCHEMBL28345614 | 0.94 | SMN1; SMN2 (0.92) | SMN1; SMN2XDHLMNATSHRADORA2A | |
| Allopurinol SCHEMBL9245971 | 0.88 | SMN1; SMN2 (0.80) | SMN1; SMN2XDHLMNATSHRADORA2A | |
| Allopurinol SCHEMBL3424532 | 0.84 | XDH (0.73) | SMN1; SMN2XDHLMNATSHRADORA2A | |
| Allopurinol SCHEMBL2323594 | 0.84 | SMN1; SMN2 (0.73) | SMN1; SMN2XDHLMNATSHRADORA2A | |
| SCHEMBL11607575 | 0.82 | XDH (0.71) | SMN1; SMN2XDHLMNATSHRADORA2A | |
| Allopurinol SCHEMBL3424531 | 0.77 | XDH (0.61) | SMN1; SMN2XDHLMNATSHRADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2111 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | claimed |
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| EP-4593859-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | Eresina, LLC (US) | 2025-08-06 | — | — | EP | claimed |
| US-20250242092-A1 | SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS | SIO2 MEDICAL PRODUCTS INC (US) | 2025-07-31 | — | — | US | claimed |
| US-12257371-B2 | SiOx barrier for pharmaceutical package and coating process | SIO2 MEDICAL PRODUCTS, LLC (US) | 2025-03-25 | — | — | US | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| WO-2024073011-A1 | TOPICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA, LLC (US) | 2024-04-04 | — | — | WO | claimed |
| WO-2024073013-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA, LLC (US) | 2024-04-04 | — | — | WO | claimed |
| US-20240074944-A1 | PECVD COATED PHARMACEUTICAL PACKAGING | OAKTREE FUND ADMINISTRATION, LLC | 2024-03-07 | — | — | US | claimed |
| CN-117241773-A | Polymer medicine bottle with standard external dimensions and reduced internal volume | SIO2医疗产品有限公司 | 2023-12-15 | — | — | CN | claimed |
| EP-1549247-A1 | DRUG RELEASE FROM ANTITHROMBOGENIC MULTI-LAYER COATED STENT | Mediplex Corporation (KR) | 2005-07-06 | — | — | EP | claimed |
| CN-1529614-A | Method of reducing side effects of chemotherapy in cancer patient | ϣ������ҩ��˾ | 2004-09-15 | — | — | CN | claimed |
| WO-2001082949-A9 | METHOD OF REDUCING SIDE EFFECTS OF CHEMOTHERAPY IN CANCER PATIENTS | SCICLONE PHARMACEUTICALS INC (US) | 2004-04-22 | — | — | WO | claimed |
| WO-2004028406-A1 | DRUG RELEASE FROM ANTITHROMBOGENIC MULTI-LAYER COATED STENT | MEDIPLEX CORPORATION (KR) | 2004-04-08 | — | — | WO | claimed |
| US-6702850-B1 | Multi-coated drug-eluting stent for antithrombosis and antirestenosis | MEDIPLEX CORPORATION KOREA (KR) | 2004-03-09 | — | — | US | claimed |
| EP-1357935-A2 | METHOD OF REDUCING SIDE EFFECTS OF CHEMOTHERAPY IN CANCER PATIENTS | Sciclone Pharmaceuticals, Inc. (US) | 2003-11-05 | — | — | EP | claimed |
| US-6589941-B1 | Preventing or reducing formation of resistance in cytostatic treatment comprising combining BVDU, a salt thereof or BVDU in protected form or in prodrug form with at least one cytostatic agent in order to prevent or reduce the formation | RESPROTECT GMBH (DE) | 2003-07-08 | — | — | US | claimed |
| US-6462017-B1 | THYMOSIN A1 IN CONJUNCTION WITH CHEMODRUG; MEDIATES LOSS OF APPETITE, LOSS OF SLEEP, FATIGUE, REDUCTION IN DAILY ACTIVITY, DECLINE IN OVERALL FEELING, DEPRESSION, NAUSEA AND VOMITING SIDE EFFECTS | SCICLONE PHARMACEUTICALS, INC. | 2002-10-08 | — | — | US | claimed |
| WO-2001082949-A2 | METHOD OF REDUCING SIDE EFFECTS OF CHEMOTHERAPY IN CANCER PATIENTS | SCICLONE PHARMACEUTICALS, INC. (US) | 2001-11-08 | — | — | WO | claimed |
| EP-0356367-A2 | Liquid medium for infusion and preservation of organs | Grino Boira, José Maria (ES) | 1990-02-28 | — | — | EP | claimed |